SAP-001 is an investigational oral agent designed to reduce serum uric acid levels by targeting a distinct renal urate reabsorption transporter.

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3b AVA-PED-301 trial.

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA vs DPP4i users.

The recall of more than 160,000 bottles of levothyroxine sodium, which went into effect June 20, was upgraded to a Class II recall on July 23. Class II recalls occur when use of the drug poses a ...

The goal of the federally recognized definition is to provide consistency in research and policy to address health concerns associated with these foods ...

Elevidys shipments paused following third death; FDA committee votes against brexpiprazole combo for PTSD; Rapiblyk now available for SVT; sleep apnea pill looks promising; JUUL e-cigarettes gain ...

Researchers say findings point to gaps in prenatal HIV detection; the majority of infants not treated for HIV infection after birth were Black.